Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:11/7/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the second of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
7. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
8. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Troy, N.Y. A new research discovery at Rensselaer ... frames for aircraft, watercraft, and automobiles. , Epoxy composites ... jets, planes, and other vehicles. Composite material frames are ... vehicle and boosts fuel efficiency. The downside is that ...
... NATURAL FUELS INDUSTRIES, INC. (Pink Sheets: VGPR) today announced ... the Company to "Fully Compliant", its highest tier for ... over-the-counter into easily identifiable tiers that inform investors whether ... a timely manner. Subsequent to NFI,s recent filing, ...
... ACF Manufacturing Drives Aggressive Conversion ProgramST. LOUIS, March 26 ... materials and services for upstream and downstream processes in ... a member of the Sigma-Aldrich Group (Nasdaq: ... of its dry powder cell culture media continuous milling ...
Cached Biology Technology:Fitter frames: Nanotubes boost structural integrity of composites 2Pink OTC Markets Moves Natural Fuels Industries to Top Tier 2SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free 2SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free 3SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free 4
(Date:4/23/2014)... Wash. -- Like a hungry diner ripping open a ... into electricity must tear open a hydrogen molecule. Now ... holding onto the two halves of its hydrogen feast. ... how to make the catalyst work better for alternative ... scientists have shown precisely where the hydrogen halves end ...
(Date:4/23/2014)... have conclusive evidence that the source of a unique ... and called the "bio-duck," is the Antarctic minke whale ... submarine personnel in the 1960s who thought it sounded ... at various locations in the Southern Ocean, but its ... February 2013, an international team of researchers deployed acoustic ...
(Date:4/23/2014)... Aires yesterday, Argentina joins the European Molecular Biology ... move strengthens the ties between the European and ... scientists access to EMBL,s world-class facilities and programs, ... its inception, fostering excellent life science research and ... of EMBL,s mission," says EMBL Director General Iain ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... Pyrazinamide (PZA) has been used in conjunction with other medications ... how the drug killed TB bacteria. PZA plays a unique ... six months and is used frequently to treat multi-drug resistant ... Hopkins Bloomberg School of Public Health, suggests that PZA binds ...
... molecular biologist Joseph M. Miano, Ph.D., and clinician Craig ... Aab Cardiovascular Research Institute and Benson is chief resident ... the University of Rochester Medical Center. Though the chance ... enthusiasm, intense curiosity and a little detective work led ...
... some of the unlikely bat habitats that could be ... the Ecological Society of America,s (ESA) 96th Annual Meeting ... other technologies relatively new to the field of ecology, ... bat behavior and the effectiveness of acoustic deterrents in ...
Cached Biology News:Researchers decode workings of mysterious, but critical TB drug 2In quest for new therapies, clinician-scientist team unlocks hidden information in human genome 2In quest for new therapies, clinician-scientist team unlocks hidden information in human genome 3In quest for new therapies, clinician-scientist team unlocks hidden information in human genome 4Scientists explore the role of aeroecology in bat conservation and ecosystem health 2Scientists explore the role of aeroecology in bat conservation and ecosystem health 3
TAR DNA binding protein...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
... High Sensitivity Freezing Point Osmometer for 10 L sample. Ideal for small volume applications, including pediatric, ... Ready to run in less than 3 minutes after turn-on. ... ... ...
Biology Products: